<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00523432</url>
  </required_header>
  <id_info>
    <org_study_id>15424A</org_study_id>
    <nct_id>NCT00523432</nct_id>
  </id_info>
  <brief_title>A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies</brief_title>
  <official_title>A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the trial is to determine the recommended phase II dose of weekly intravenous
      topotecan in combination with a fixed dose (25 mg or 15 mg) of weekly intravenous
      temsirolimus in patients with and without prior pelvic radiation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability of regimen</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Genital Neoplasms, Female</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A will consist of subjects without prior pelvic radiation or with radiation to a field smaller than the whole pelvis. Subjects will receive weekly CCI-779 and topotecan at the assigned dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm A will consist of subjects with prior whole pelvic radiation. Subjects will receive weekly CCI-779 and topotecan at the assigned dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan</intervention_name>
    <description>Weekly doses via IV infusion. Dose will be assigned based on time of study entry.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CCI-779 (temsirolimus)</intervention_name>
    <description>Weekly 25mg dose via IV infusion.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed recurrent or metastatic ovarian carcinoma, fallopian tube
             carcinoma, primary peritoneal carcinoma, cervical carcinoma, endometrial carcinoma,
             vulvar carcinoma, vaginal carcinoma, or carcinosarcoma of the ovary, endometrium or
             cervix.

          -  Prior Therapy: at least one and may have up to three prior cytotoxic chemotherapeutic
             regimens for the management of primary disease.

          -  Must be at least 18 years of age.

          -  GOG performance status must be 0 or 1.

          -  Patients must have adequate organ and marrow function as defined below:

               -  hemoglobin ≥10g/dL

               -  absolute neutrophil count ≥1,500/uL

               -  platelets ≥100,000/uL

               -  total bilirubin below the institutional upper limit of normal

               -  AST(SGOT)/ALT(SGPT) below the institutional upper limit of normal

               -  creatinine below the institutional upper limit of normal

               -  cholesterol ≤ 350 mg/dL (fasting)

               -  triglycerides ≤ 400 mg/dL (fasting)

               -  albumin ≥ 3.0 mg/dL

          -  negative pregnancy test for women able to have children

          -  Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Prior therapy with topotecan

          -  More than 3 prior cytotoxic chemotherapeutic regimens or treatment with temsirolimus
             or any other mTOR inhibitor

          -  Concomitant hormonal therapy or radiation therapy

          -  Clinically significant infections or other medical problems of significant severity

          -  History of unstable angina or myocardial infarction within the past six months

          -  Known brain metastases unless the metastases have been controlled by prior surgery or
             radiotherapy, and the patient has been neurologically stable and off of steroids for
             at least 4 weeks.

          -  Any requirement for oxygen

          -  Cannot be receiving potent enzyme-inducing antiepileptic drugs (EIAEDs; e.g.,
             phenytoin, carbamazepine, phenobarbital) nor any other potent CYP3A4 inducer such as
             rifampin or St. John's wort, as these may decrease temsirolimus levels. Use of agents
             that potently inhibit CYP3A4 (and hence may raise temsirolimus levels), such as
             ketoconazole, is discouraged, but not specifically prohibited.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gini Fleming, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Temkin SM, Yamada SD, Fleming GF. A phase I study of weekly temsirolimus and topotecan in the treatment of advanced and/or recurrent gynecologic malignancies. Gynecol Oncol. 2010 Jun;117(3):473-6. doi: 10.1016/j.ygyno.2010.02.022. Epub 2010 Mar 28.</citation>
    <PMID>20347480</PMID>
  </results_reference>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2007</study_first_submitted>
  <study_first_submitted_qc>August 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2007</study_first_posted>
  <last_update_submitted>September 4, 2013</last_update_submitted>
  <last_update_submitted_qc>September 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ovarian cancer</keyword>
  <keyword>cervical cancer</keyword>
  <keyword>uterine cancer</keyword>
  <keyword>fallopian tube cancer</keyword>
  <keyword>endometrial cancer</keyword>
  <keyword>vaginal cancer</keyword>
  <keyword>peritoneal cancer</keyword>
  <keyword>reproductive cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Genital Neoplasms, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topotecan</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

